Liver cancer is the third leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) accounting for approximately 90% of primary liver cancers. Advances in diagnostic and therapeutic tools, along with improved understanding of their application, are transforming patient treatment. Integrating these innovations into clinical practice presents challenges and necessitates guidance. These clinical practice guidelines offer updated advice for managing patients with HCC and provide a comprehensive review of pertinent data. Key updates from the 2018 EASL guidelines include personalised surveillance based on individual risk assessment and the use of new tools, standardisation of liver imaging procedures and diagnostic criteria, use of minimally invasive surgery in complex cases together with updates on the integrated role of liver transplantation, transitions between surgical, locoregional, and systemic therapies, the role of radiation therapies, and the use of combination immunotherapies at various stages of disease. Above all, there is an absolute need for a multiparametric assessment of individual risks and benefits, considering the patient's perspective, by a multidisciplinary team encompassing various specialties.

中文翻译：

---

EASL 肝细胞癌管理临床实践指南


肝癌是全球癌症相关死亡的第三大原因，肝细胞癌 （HCC） 约占原发性肝癌的 90%。诊断和治疗工具的进步以及对其应用的深入了解正在改变患者的治疗方式。将这些创新整合到临床实践中会带来挑战，需要指导。这些临床实践指南为 HCC 患者的管理提供了最新的建议，并对相关数据进行了全面回顾。2018 年 EASL 指南的主要更新包括基于个体风险评估和新工具使用的个性化监测、肝脏成像程序和诊断标准的标准化、在复杂病例中使用微创手术以及肝移植综合作用的更新、手术、局部和全身治疗之间的过渡、放射治疗的作用、 以及在疾病不同阶段使用联合免疫疗法。最重要的是，绝对需要由包含各种专业的多学科团队从患者的角度出发，对个体风险和益处进行多参数评估。